Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.
Identifieur interne : 001450 ( Main/Corpus ); précédent : 001449; suivant : 001451Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.
Auteurs : Khalid Shaikh ; Chandrama Shrestha ; Deep DuttaSource :
- JPMA. The Journal of the Pakistan Medical Association [ 0030-9982 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents, Immunoglobulins, Intravenous.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Chelation Therapy, Humans, Pandemics, SARS-CoV-2.
Abstract
Novel coronavirus disease (COVID-19) infection is a global pandemic, of high infectivity, variable mortality, with currently no established treatment. This review summarizes different molecules which are being evaluated for COVID19 treatment. PubMed and Medline, search for articles published to March 2020 was done using terms "COVID19" OR "corona-virus 2019" OR "2019-nCoV" or "severe acute respiratory syndrome coronavirus" AND "treatment". As of today, we have >350 RCTs happening with different agents. COVID19 treatment agents can be broadly classified into immuno-modulators (prevent hyperimmune-activation and cytokine storm) and anti-viral therapies (prevent virus entry, replication or viricidal). Hydroxychloroquine/chloroquine, Interferon-l, glucocorticoids, interleukin antagonists, Ulinastatin, intravenous immunoglobulins, plasmapheresis are main immunomodulators showing initial positive outcomes. Umifenovir. Lopinavir/Ritonavir, Ribavirin, remdesivir and Ravipiravir are some of the major antiviral agents showing initial encouraging results. It may be concluded that the most successful regimen is going to be multi-drug therapy, a combination of immunomodulatory agent with anti-viral agent.
DOI: 10.5455/JPMA.22
PubMed: 32515383
Links to Exploration step
pubmed:32515383Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.</title><author><name sortKey="Shaikh, Khalid" sort="Shaikh, Khalid" uniqKey="Shaikh K" first="Khalid" last="Shaikh">Khalid Shaikh</name><affiliation><nlm:affiliation>Department of Medicine, Royal Oman Police Hospital, Muscat, Oman.</nlm:affiliation></affiliation></author><author><name sortKey="Shrestha, Chandrama" sort="Shrestha, Chandrama" uniqKey="Shrestha C" first="Chandrama" last="Shrestha">Chandrama Shrestha</name><affiliation><nlm:affiliation>Nepal Diabetes Society, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Dutta, Deep" sort="Dutta, Deep" uniqKey="Dutta D" first="Deep" last="Dutta">Deep Dutta</name><affiliation><nlm:affiliation>Center for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Clinics, Dwarka, New Delhi, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32515383</idno><idno type="pmid">32515383</idno><idno type="doi">10.5455/JPMA.22</idno><idno type="wicri:Area/Main/Corpus">001450</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001450</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.</title><author><name sortKey="Shaikh, Khalid" sort="Shaikh, Khalid" uniqKey="Shaikh K" first="Khalid" last="Shaikh">Khalid Shaikh</name><affiliation><nlm:affiliation>Department of Medicine, Royal Oman Police Hospital, Muscat, Oman.</nlm:affiliation></affiliation></author><author><name sortKey="Shrestha, Chandrama" sort="Shrestha, Chandrama" uniqKey="Shrestha C" first="Chandrama" last="Shrestha">Chandrama Shrestha</name><affiliation><nlm:affiliation>Nepal Diabetes Society, Kathmandu, Nepal.</nlm:affiliation></affiliation></author><author><name sortKey="Dutta, Deep" sort="Dutta, Deep" uniqKey="Dutta D" first="Deep" last="Dutta">Deep Dutta</name><affiliation><nlm:affiliation>Center for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Clinics, Dwarka, New Delhi, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">JPMA. The Journal of the Pakistan Medical Association</title><idno type="ISSN">0030-9982</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chelation Therapy (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Humans (MeSH)</term><term>Immunoglobulins, Intravenous (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Immunoglobulins, Intravenous</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Chelation Therapy</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Novel coronavirus disease (COVID-19) infection is a global pandemic, of high infectivity, variable mortality, with currently no established treatment. This review summarizes different molecules which are being evaluated for COVID19 treatment. PubMed and Medline, search for articles published to March 2020 was done using terms "COVID19" OR "corona-virus 2019" OR "2019-nCoV" or "severe acute respiratory syndrome coronavirus" AND "treatment". As of today, we have >350 RCTs happening with different agents. COVID19 treatment agents can be broadly classified into immuno-modulators (prevent hyperimmune-activation and cytokine storm) and anti-viral therapies (prevent virus entry, replication or viricidal). Hydroxychloroquine/chloroquine, Interferon-l, glucocorticoids, interleukin antagonists, Ulinastatin, intravenous immunoglobulins, plasmapheresis are main immunomodulators showing initial positive outcomes. Umifenovir. Lopinavir/Ritonavir, Ribavirin, remdesivir and Ravipiravir are some of the major antiviral agents showing initial encouraging results. It may be concluded that the most successful regimen is going to be multi-drug therapy, a combination of immunomodulatory agent with anti-viral agent.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32515383</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0030-9982</ISSN><JournalIssue CitedMedium="Internet"><Volume>70(Suppl 3)</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>JPMA. The Journal of the Pakistan Medical Association</Title><ISOAbbreviation>J Pak Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.</ArticleTitle><Pagination><MedlinePgn>S69-S73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5455/JPMA.22</ELocationID><Abstract><AbstractText>Novel coronavirus disease (COVID-19) infection is a global pandemic, of high infectivity, variable mortality, with currently no established treatment. This review summarizes different molecules which are being evaluated for COVID19 treatment. PubMed and Medline, search for articles published to March 2020 was done using terms "COVID19" OR "corona-virus 2019" OR "2019-nCoV" or "severe acute respiratory syndrome coronavirus" AND "treatment". As of today, we have >350 RCTs happening with different agents. COVID19 treatment agents can be broadly classified into immuno-modulators (prevent hyperimmune-activation and cytokine storm) and anti-viral therapies (prevent virus entry, replication or viricidal). Hydroxychloroquine/chloroquine, Interferon-l, glucocorticoids, interleukin antagonists, Ulinastatin, intravenous immunoglobulins, plasmapheresis are main immunomodulators showing initial positive outcomes. Umifenovir. Lopinavir/Ritonavir, Ribavirin, remdesivir and Ravipiravir are some of the major antiviral agents showing initial encouraging results. It may be concluded that the most successful regimen is going to be multi-drug therapy, a combination of immunomodulatory agent with anti-viral agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shaikh</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Royal Oman Police Hospital, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Chandrama</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nepal Diabetes Society, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Deep</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Endocrinology, Diabetes, Arthritis & Rheumatism (CEDAR) Superspeciality Clinics, Dwarka, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Pakistan</Country><MedlineTA>J Pak Med Assoc</MedlineTA><NlmUniqueID>7501162</NlmUniqueID><ISSNLinking>0030-9982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015913" MajorTopicYN="N">Chelation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19, Wuhan virus, hydroxychloroquine, remedesevir, antihelminth, anti-cytokine therapy, antiviral.
</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32515383</ArticleId><ArticleId IdType="doi">10.5455/JPMA.22</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32515383
|texte= Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32515383" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |